

**The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.**

[SI Reporter](#) | Mumbai Last Updated at June 22, 2018 10:05 IST



Patients prefer better outcome to brand in new treatments, says report

[AstraZeneca Pharma India](#) was up 5% to Rs 1,416 on the BSE in early morning trade after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.

“The company has received import & market permission for [Durvalumab](#) (Imfinzi™) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of [durvalumab](#) (Imfinzi™) in India, subject to the receipt of further related statutory approvals and licenses,” [AstraZeneca Pharma India](#) said in a press release.

[Durvalumab](#) provides a treatment option for patient with locally advanced, unresectable non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab is a patented product of AstraZeneca global, it added.

The company said Durvalumab is the only immunotherapy approved for patients with unresectable stage III non-small cell lung cancer (NSCLC). The medicine was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.

Shares of AstraZeneca Pharma hit a 52-week high of Rs 1,515 on June 19, 2018 in intra-day trade, has rallied 21% in past two weeks. On comparison, the S&P BSE Sensex was down 0.12% during the period.

At 09:45 am; the stock was trading 3% higher at Rs 1,392 as compared to 0.22% decline in the benchmark index. A combined 133,393 shares changed hands on the BSE and NSE.

First Published: Fri, June 22 2018. 10:00 IST

PREVIOUS STORY

NEXT STORY

